AAOS News: Bioventus Introduced New Spine Surgery, Osteoarthritis Products

NEWS

Bioventus introduced several new products at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) March 1-5 in the Orange County Convention Center. These included GELSYN-3, a three-injection, hyaluronic-acid (HA) based product for pain relief associated with osteoarthritis (OA) of the knee. HA is a naturally occurring molecule that provides for lubrication and cushioning in a normal joint. 

Bioventus also introduced CellXtract, a novel cell and bone marrow extraction tool; and SIGNAFUSE Bioactive Bonegraft Putty, which is comprised of a bi-phasic mineral composite combined with a patented bioactive glass and resorbable polymer carrier providing surgeons with exceptional handling properties.
 
“Bioventus is very pleased to introduce a full portfolio of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals this week at AAOS,” said Tony Bihl, CEO of Bioventus. “We are also excited to speak with attendees about GELSYN-3, our newest HA as well as the rest of our active healing therapies product portfolio. It’s our goal to provide customers with leading orthobiologic products that heal patients quickly and safely while helping them resume and enjoy active lives.”
 
Also on display was EXOGEN Ultrasound Bone Healing System, indicated for the treatment of established non-unions and indicated fresh fractures; SUPARTZ FX, a five-injection HA for treatment of pain in the knee due to OA; DUROLANE, a single-injection stabilized HA based upon a natural, safe and proven technology called NASHA, and indicated for the treatment of mild to moderate OA pain in a variety of joints; and OsteoAMP Allogeneic Morphogenetic Proteins, a uniquely processed allograft bone graft substitute and a suite of additional synthetic and allograft bone graft solutions added with the recent BioStructures acquisition.